Thermo Fisher Scientific issues $3.8B in Senior Notes
Overview
| Deal Type |
Debt Capital Markets |
|---|---|
| Size |
$1 Billion Senior Notes due 2031 $750 Million Senior Notes due 2033 $1.3 Billion Senior Notes due 2036 $750 Million Senior Notes due 2046 |
| Our Role |
Co-Manager |
KeyBanc Capital Markets and Cain Brothers, a division of KeyBanc Capital Markets, acted as Co-Manager in the $3.8 billion offering of Senior Notes for Thermo Fisher Scientific Inc. (NYSE: TMO).
Cain Brothers and KeyBanc Capital Markets served as Co-Manager due to its industry expertise and long-standing relationship with the Company. Proceeds will be used to fund the cash consideration related to the acquisition of Clario Holdings as well as general corporate purposes.
Thermo Fisher manufactures scientific instruments, consumables, and chemicals. The Company offers analytical instruments, laboratory equipment, software, and supplies to pharmaceutical and biotech companies, hospitals and clinical diagnostic labs, universities, research institutions, and government agencies.
Eric Peiffer
KeyBanc Capital Markets Inc., Member FINRA/SIPC, and KeyBank National Association ("KeyBank N.A.") are separate, but affiliated companies. Securities products and services are offered by KeyBanc Capital Markets Inc. and its licensed securities representatives.
Securities products and services: Not FDIC Insured • No Bank Guarantee • May Lose Value
Banking products and services are offered by KeyBank N.A. All credit, loan, and leasing products are subject to collateral and/or credit approval terms, conditions, and availability and subject to change.




















































